The Impact of Synergistic Therapy Between Colistin and Meropenem on Outcomes of People With Pneumonia or Bloodstream Infection Due to Carbapenem-Resistant Gram-Negative Pathogens
Clinical Infectious Diseases · 17.03.2026 · 82 (3) · 391-398
DOI: 10.1093/cid/ciaf398 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Clinical Infectious Diseases, online erschienen am 19.07.2025. Verfasst von Mariya Huralska und 32 weiteren Autor:innen. Beteiligte Einrichtung: Division of Infectious Diseases, Department of Medicine, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, USA. Hauptthemen laut MEDLINE: Colistin, Meropenem, Anti-Bacterial Agents, Gram-Negative Bacterial Infections. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: National Institute of Allergy and Infectious Diseases, Division of Microbiology and Infectious Diseases.
Abstract (Originalsprache)
Background
Colistin, a last-line treatment for carbapenem-resistant Gram-negative bacilli (CRGNB), is frequently used in combination with meropenem because these agents often demonstrate in vitro synergy. Using data from the OVERCOME trial comparing colistin + meropenem to colistin + placebo for treatment of pneumonia or bloodstream infection due to CRGNB, we evaluated the impact of synergistic therapy on outcomes.
Methods
In vitro synergy testing between colistin and meropenem was conducted using 24-hour time-kill analysis; synergy was defined as >2-log reduction in colony-forming units/mL compared to the most active single agent. Patients receiving synergistic combination therapy were compared to patients receiving functional colistin monotherapy (colistin alone or combination therapy without synergy). Outcomes included mortality, clinical failure, and microbiologic cure. Adjusted analyses controlled for variables on which randomization was stratified and confounders.
Results
A total of 146 subjects receiving synergistic combination therapy and 261 subjects receiving functional monotherapy were included. Most had pneumonia (70%), CR Acinetobacter baumannii infection (79%) and were in intensive care (69%). Acinetobacter baumannii was more common in those receiving synergistic combination therapy than functional monotherapy (P < .001). Mortality rates were similar (38.3% and 41.4%, respectively). In adjusted analyses, synergistic combination therapy was associated with significantly lower clinical failure rates (55.3%, 64.3%, adjusted odds ratio [aOR] 0.62, P = .049), with consistent findings in pneumonia (62.6%, 71.8%, aOR 0.55, P = .04) and A. baumannii subgroups (57.4%, 69.4%, aOR 0.60, P = .06). Microbiologic cure rates were similar.
Conclusions
Colistin-based, synergistic combination treatment with meropenem (compared to nonsynergistic colistin-based therapy) was associated with decreased clinical failure, particularly in people with pneumonia and A. baumannii.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Infectious Diseases, Department of Medicine, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, USA.
- Department of Clinical Pharmacy, University of Michigan College of Pharmacy, Ann Arbor, MI, USA.
- Anti-Infective Research Laboratory, Eugene Applebaum College of Pharmacy and Health Science, Wayne State University, Detroit, MI, USA.
- Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California, San Diego, CA, USA.
- Unit of Infection Control, Shamir (Assaf Harofeh) Medical Center, Be'er Ya'akov, Israel.
- Division of Infectious Diseases and Tropical Medicine, Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.
ORCID-Profile: Mariya Huralska, Jacinda C Abdul-Mutakabbir, Visanu Thamlikitkul, Cheng-Hsun Chiu, George Daikos, Emanuele Durante-Mangoni, Mical Paul, Emmanuel Roilides, Michael Samarkos, Gopi Patel, David P Calfee, Laura Power, Laura Susick, George Divine, Keith S Kaye
Förderung
- National Institute of Allergy and Infectious Diseases
- Division of Microbiology and Infectious Diseases
Zitieren
APA
Huralska, M., Pogue, J. M., Rybak, M., Abdul-Mutakabbir, J. C., Stamper, K., Marchaim, D., Thamlikitkul, V., Carmeli, Y., Chiu, C. H., Daikos, G., Dhar, S., Durante-Mangoni, E., Gikas, A., Kotanidou, A., Paul, M., Roilides, E., Samarkos, M., Sims, M., Tancheva, D., …, & Kaye, K. S. (2026). The Impact of Synergistic Therapy Between Colistin and Meropenem on Outcomes of People With Pneumonia or Bloodstream Infection Due to Carbapenem-Resistant Gram-Negative Pathogens. Clinical Infectious Diseases, 82(3), 391-398. https://doi.org/10.1093/cid/ciaf398
Vancouver
Huralska M, Pogue JM, Rybak M, Abdul-Mutakabbir JC, Stamper K, Marchaim D, et al. The Impact of Synergistic Therapy Between Colistin and Meropenem on Outcomes of People With Pneumonia or Bloodstream Infection Due to Carbapenem-Resistant Gram-Negative Pathogens. Clinical Infectious Diseases. 2026;82(3):391-398. doi:10.1093/cid/ciaf398
BibTeX
@article{Huralska2026,
author = {Huralska, Mariya and Pogue, Jason M and Rybak, Michael and Abdul-Mutakabbir, Jacinda C and Stamper, Kyle and Marchaim, Dror and Thamlikitkul, Visanu and Carmeli, Yehuda and Chiu, Cheng-Hsun and Daikos, George and Dhar, Sorabh and Durante-Mangoni, Emanuele and Gikas, Achilles and Kotanidou, Anastasia and Paul, Mical and Roilides, Emmanuel and Samarkos, Michael and Sims, Matthew and Tancheva, Dora and Tsiodras, Sotirios and Kett, Daniel H and Patel, Gopi and Calfee, David P and Leibovici, Leonard and Power, Laura and Munoz-Price, Silvia and Shaikh, Hamadullah and Susick, Laura and Latack, Katie and Chiou, Christine and Divine, George and Ghazyaran, Varduhi and Kaye, Keith S},
title = {The Impact of Synergistic Therapy Between Colistin and Meropenem on Outcomes of People With Pneumonia or Bloodstream Infection Due to Carbapenem-Resistant Gram-Negative Pathogens},
journal = {Clinical Infectious Diseases},
year = {2026},
volume = {82},
number = {3},
pages = {391--398},
doi = {10.1093/cid/ciaf398}
}
EUVIMED